Innate Pharma SA has entered a strategic licensing partnership with Swedish Orphan Biovitrum AB, better known as Sobi, for lacutamab, its investigational anti-KIR3DL2 antibody being developed for cutaneous T-cell lymphoma. The agreement provides Innate Pharma with $75 million payable at closing and creates a route to finance the planned TELLOMAK-3 confirmatory Phase 3 study, while giving Sobi exclusive global commercialization rights if lacutamab reaches potential accelerated approval.
The economics extend well beyond the initial payment. Innate Pharma can receive up to another $40 million from near-term development milestones linked to Sézary syndrome and as much as $465 million connected with Sobi potentially taking full development rights and with subsequent regulatory and commercial milestones. That places the total potential consideration at up to $580 million before royalties, although most of that amount remains contingent rather than guaranteed; Innate Pharma would also receive tiered double-digit royalties on net sales.
More important than the headline deal value is what the transaction removes from lacutamab’s immediate development path. As recently as May 2026, Innate Pharma was saying TELLOMAK-3 remained planned for the second half of 2026 but was dependent on securing non-dilutive financing through options including pharmaceutical partnering or royalty structures. At March 31, the company reported €25.4 million of cash, cash equivalents and financial assets, alongside €20.3 million of financial liabilities, making financing of another pivotal programme a material strategic constraint.
The Sobi agreement therefore looks less like a conventional late-stage licensing transaction and more like a financing and commercialization solution built around a specific regulatory opportunity. Innate Pharma keeps responsibility for conducting TELLOMAK-3, preserving involvement through the pivotal development stage, while Sobi gains the commercial position it would need if the proposed accelerated approval strategy succeeds. The transaction remains subject to closing conditions, including transaction-related antitrust clearance.
Why does the Sobi partnership matter more for lacutamab than the $580m headline value suggests?
Lacutamab had already reached a point where its next major challenge was no longer simply demonstrating activity in another early-stage study. The United States Food and Drug Administration completed its review of the TELLOMAK-3 protocol in November 2025 without further comments, allowing the confirmatory study to proceed. TELLOMAK-3 is designed as an open-label, randomized Phase 3 trial covering Sézary syndrome and mycosis fungoides in patients who have failed at least one previous systemic therapy.
That regulatory progress created a different problem. A Phase 3 study requires substantially greater financial and operational commitment than the Phase 2 programme that established the current clinical rationale, while Innate Pharma was simultaneously funding other pipeline priorities. The company’s March 2026 results made that tension explicit, stating that TELLOMAK-3 initiation depended on non-dilutive financing.
Sobi now fills that gap without Innate Pharma having to fund the programme exclusively through its existing balance sheet or an equity raise. The $75 million closing payment is material relative to Innate Pharma’s reported March cash position, but its strategic effect is arguably larger than the simple comparison suggests. The partnership also transfers much of the future commercial scaling challenge to a company whose business is already centred on rare diseases and which generated SEK 28 billion in revenue during 2025.
The structure also leaves Sobi with an incentive to wait for additional evidence before assuming the entire development programme. It receives exclusive global commercialization rights upon potential accelerated approval, but its ability to take full global development rights follows positive Phase 3 results. That staging reduces Sobi’s exposure before confirmatory evidence while allowing Innate Pharma to monetize lacutamab earlier in the regulatory process.
What does TELLOMAK Phase 2 actually establish about lacutamab in Sézary syndrome?
Lacutamab is a humanized monoclonal antibody targeting KIR3DL2, an inhibitory receptor expressed by malignant T cells in a substantial proportion of cutaneous T-cell lymphoma cases. Its lead clinical opportunity has increasingly concentrated on Sézary syndrome, the aggressive leukemic form of cutaneous T-cell lymphoma, where Innate Pharma has accumulated the strongest combination of clinical activity, response durability and regulatory engagement.
The completed TELLOMAK Phase 2 study was an open-label, multi-cohort trial enrolling 170 patients with Sézary syndrome or mycosis fungoides. ClinicalTrials.gov records the study as completed, with an actual primary completion and study completion date of January 8, 2026. The design did not include a randomized comparator, an important limitation when interpreting efficacy estimates and one reason the confirmatory programme matters.
Longer-term follow-up presented by Innate Pharma reported a global objective response rate of 42.9% in heavily pretreated patients with Sézary syndrome and a median duration of response of 25.6 months. In mycosis fungoides, the company reported a 19.6% global response rate and a median response duration of 13.8 months, with responses occurring across patients irrespective of baseline KIR3DL2 expression. These are company-reported Phase 2 findings rather than randomized evidence of superiority over an established treatment.
The distinction is important. A durable response signal in a difficult-to-treat population can justify further development and regulatory discussion, but an open-label Phase 2 programme cannot answer every question about comparative clinical benefit. TELLOMAK-3 is intended to provide that stronger evidentiary layer through randomized cohorts and progression-free survival assessed by blinded central review.
How will TELLOMAK-3 test lacutamab against existing CTCL treatment options?
The Sézary syndrome portion of TELLOMAK-3 is planned to enrol patients previously treated with mogamulizumab and randomize them 1:1 between lacutamab and romidepsin. The separate mycosis fungoides cohort will randomize patients 1:1 between lacutamab and mogamulizumab. Progression-free survival will serve as the primary endpoint in both cohorts.
That design is commercially consequential because it moves lacutamab from single-arm response assessment into a comparative setting. If the study demonstrates a convincing progression-free survival benefit with an acceptable safety profile, the evidence would provide considerably stronger support for positioning the antibody within the CTCL treatment sequence. Conversely, a Phase 3 result that fails to reproduce the apparent benefit seen in TELLOMAK would materially weaken the broader development thesis.
The Phase 3 population is also broader in treatment history than the population supporting the existing United States Breakthrough Therapy Designation. The FDA granted that designation in February 2025 for adults with relapsed or refractory Sézary syndrome after at least two prior systemic therapies, including mogamulizumab. TELLOMAK-3 is planned in patients who have failed at least one prior systemic treatment, giving the programme the potential to generate evidence relevant to a wider treatment setting, subject to the eventual trial results and regulatory assessment.
Could lacutamab reach accelerated approval before TELLOMAK-3 produces its final Phase 3 result?
This is the most important regulatory feature of the transaction, but also the easiest one to overstate. Innate Pharma and Sobi are preparing around a potential accelerated approval filing for lacutamab in Sézary syndrome once TELLOMAK-3 is underway. The FDA had previously provided feedback that the existing evidence package and confirmatory-study plan could potentially support such a pathway.
Accelerated approval is not assured simply because a confirmatory study begins, nor do Breakthrough Therapy, Fast Track or orphan designations constitute approval. They provide regulatory mechanisms intended to facilitate development or review under defined circumstances. The eventual filing would still need to satisfy the FDA that the evidence supports the proposed indication and that the regulatory requirements for the accelerated pathway have been met.
The partnership structure appears designed around this sequence. Innate Pharma conducts TELLOMAK-3 and supports the planned accelerated approval filing in Sézary syndrome. If approval is obtained, Sobi receives exclusive global commercialization rights, while positive Phase 3 results could allow it to assume full global development rights. The completed Phase 3 programme would then be expected to support potential full approval in Sézary syndrome and a full-approval application in mycosis fungoides.
That creates several distinct value inflection points rather than one binary approval event. Trial initiation, a potential accelerated approval submission, regulatory acceptance and review, any eventual accelerated approval decision, Phase 3 progression-free survival results and subsequent full-approval applications each represent separate hurdles.
What does lacutamab’s previous FDA clinical hold reveal about the safety evidence?
Lacutamab’s development history also includes a regulatory interruption that provides useful context for assessing the programme. The FDA placed the lacutamab Investigational New Drug application on partial clinical hold in October 2023 following a patient death that was initially considered associated with hemophagocytic lymphohistiocytosis.
The agency lifted that partial hold in January 2024. Innate Pharma said the FDA reviewed the case after the company and an independent steering committee concluded that the death was related to aggressive disease progression rather than lacutamab treatment. The lifting of the hold allowed the clinical programme to continue, but it remains appropriate to view safety through the cumulative clinical evidence rather than treating resolution of one regulatory event as proof that no treatment risks exist.
Subsequent TELLOMAK disclosures have described the observed safety profile as favourable, and the FDA later granted Breakthrough Therapy Designation and cleared the TELLOMAK-3 protocol to proceed. Those developments strengthen the regulatory footing of the programme, while Phase 3 will provide a larger comparative dataset with which to evaluate benefit and risk.
Why Sobi could be a logical commercial home for a rare T-cell lymphoma therapy
The commercial logic is straightforward. Cutaneous T-cell lymphoma is a rare disease area requiring specialist physician engagement rather than the infrastructure associated with a mass-market primary-care medicine. Sobi has built its business around rare diseases and already operates across Europe, North America, the Middle East, Asia and Australia, creating a commercial footprint that Innate Pharma would otherwise need to build or access through another partner.
For Sobi, the transaction provides a late-stage rare-disease oncology programme with multiple regulatory designations and an already defined confirmatory pathway. It also avoids acquiring the entire programme immediately. The company first receives commercialization rights contingent on potential approval and has a later route to full development control if Phase 3 is positive.
For Innate Pharma, that structure preserves exposure through milestones and double-digit royalties while limiting the need to independently create a worldwide commercial organization around a single late-stage asset. It also fits the biotechnology company’s broader strategic model of advancing internally generated antibody programmes and then using partnerships to share development or commercialization responsibilities.
What must happen before the Innate Pharma and Sobi lacutamab deal can create lasting value?
The partnership solves an immediate strategic problem, but it does not solve the clinical one. TELLOMAK-3 still has to begin, recruit an appropriate population and generate evidence capable of supporting the regulatory ambitions now embedded in the deal. The initial accelerated approval strategy for Sézary syndrome will depend on FDA assessment of the complete filing package, while longer-term value rests substantially on whether randomized Phase 3 data confirm the activity observed in TELLOMAK.
The transaction also should not be read as a $580 million cash payment to Innate Pharma. Only $75 million is payable at closing, with another $40 million linked to near-term Sézary syndrome development milestones and the remaining potential payments dependent on Sobi’s development-rights option and future regulatory and commercial achievements. Closing itself is still subject to specified conditions, including antitrust clearance.
What has changed is the feasibility of getting to those milestones. Innate Pharma entered 2026 with a Phase 3-ready asset but a financing requirement attached to its pivotal study. The Sobi partnership provides the capital, rare-disease commercial infrastructure and longer-term development framework that were missing.
The next meaningful test is therefore not the theoretical $580 million ceiling. It is whether TELLOMAK-3 can move from a financed plan into an operating Phase 3 programme and whether the randomized evidence ultimately validates the unusually durable responses reported in Sézary syndrome. If it does, Sobi will have secured a differentiated late-stage rare lymphoma asset and Innate Pharma will retain milestone and royalty exposure without having to build the entire global commercial platform itself. If it does not, much of the headline transaction value will remain exactly where it is today: contingent.
